Abstract:Background & Aims: Chronic liver injury often results in the activation of hepatic myofibroblasts and the development of liver fibrosis. Hepatic myofibroblasts may originate from 3 major sources: hepatic stellate cells (HSCs), portal fibroblasts (PFs), and fibrocytes, with varying contributions depending on the etiology of liver injury. Here, we assessed the composition of hepatic myofibroblasts in multidrug resistance gene 2 knockout (Mdr2(-/-)) mice, a genetic model that resembles primary sclerosing cholangitis in patients. Methods: Mdr2(-/-) mice expressing a collagen-GFP reporter were analyzed at different ages. Hepatic non-parenchymal cells isolated from collagen-GFP Mdr2(-/-) mice were sorted based on collagen-GFP and vitamin A. An NADPH oxidase (NOX) 1/4 inhibitor was administrated to Mdr2(-/-) mice aged 12-16 weeks old to assess the therapeutic approach of targeting oxidative stress in cholestatic injury. Results: Thy1(+) activated PFs accounted for 26%, 51%, and 54% of collagen-GFP(+) myofibroblasts in Mdr2(-/-) mice at 4, 8, and 16 weeks of age, respectively. The remaining collagen-GFP(+) myofibroblasts were composed of activated HSCs, suggesting that PFs and HSCs are both activated in Mdr2(-/-) mice. Bone-marrow-derived fibrocytes minimally contributed to liver fibrosis in Mdr2(-/-) mice. The development of cholestatic liver fibrosis in Mdr2(-/-) mice was associated with early recruitment of Gr1(+) myeloid cells and upregulation of pro-inflammatory cytokines (4 weeks). Administration of a NOX inhibitor to 12-week-old Mdr2(-/-) mice suppressed the activation of myofibroblasts and attenuated the development of cholestatic fibrosis. Conclusions: Activated PFs and activated HSCs contribute to cholestatic fibrosis in Mdr2(-/-) mice, and serve as targets for antifibrotic therapy. Lay summary: Activated portal fibroblasts and hepatic stellate cells, but not fibrocytes, contributed to the production of the fibrous scar in livers of Mdr2(-/-) mice, and these cells can serve as targets for antifibrotic therapy in cholestatic injury. Therapeutic inhibition of the enzyme NADPH oxidase (NOX) in Mdr2(-/-) mice reversed cholestatic fibrosis, suggesting that targeting NOXs may be an effective strategy for the treatment of cholestatic fibrosis. (C) 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Mediator subunit MED1 deficiency prevents carbon tetrachloride-induced hepatic fibrosis in mice

Transcription Coactivator Mediator Subunit MED1 is Required for the Development of Fatty Liver in the Mouse

Mediator MED23 Regulates Inflammatory Responses and Liver Fibrosis

MED1 Deficiency in Macrophages Aggravates Isoproterenol-Induced Cardiac Fibrosis in Mice

Med1 inhibits ferroptosis and alleviates liver injury in acute liver failure via Nrf2 activation

Hepatocyte-specific Deficiency of Nrf2 Exacerbates Carbon Tetrachloride-Induced Liver Fibrosis Via Aggravated Hepatocyte Injury and Subsequent Inflammatory and Fibrogenic Responses.

Deletion of GPR81 Activates CREB/Smad7 Pathway and Alleviates Liver Fibrosis in Mice

miR-140-5p attenuates hepatic fibrosis by directly targeting TGFβR1

Aldehyde Dehydrogenase 2 Activation Ameliorates Ccl4-Induced Chronic Liver Fibrosis In Mice By Up-Regulating Nrf2/Ho-1 Antioxidant Pathway

TIMP-1 Promotes Expression of MCP-1 and Macrophage Migration by Inducing Fli-1 in Experimental Liver Fibrosis

Activated Hepatic Stellate Cells and Portal Fibroblasts Contribute to Cholestatic Liver Fibrosis in MDR2 Knockout Mice

CAT1 Silencing Inhibits TGF-β1-induced Mouse Hepatic Stellate Cell Activation in Vitro and Hepatic Fibrosis in Vivo.

Hepatocyte FoxO1 Deficiency Protects From Liver Fibrosis via Reducing Inflammation and TGF-β1-mediated HSC Activation

Targeting Follistatin like 1 ameliorates liver fibrosis induced by carbon tetrachloride through TGF-β1-miR29a in mice

Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling

TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation

[Hyperlipidemia in Hepatic MED1 Deficient Mice in Response to Fasting].

Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Deficiency Exacerbates Carbon Tetrachloride-Induced Liver Injury and Fibrosis in Mice: Involvement of Hepatocyte STAT3 in TIMP-1 Production

Inhibition of heme-thiolate monooxygenase CYP1B1 prevents hepatic stellate cell activation and liver fibrosis by accumulating trehalose

Immune response gene 1 deficiency impairs Nrf2 activation and aggravates liver fibrosis in mice

MED1 Deficiency in Macrophages Accelerates Intimal Hyperplasia Via ROS Generation and Inflammation